about
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancerA phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.A church-based intervention to promote informed decision making for prostate cancer screening among African American menChemotherapy for prostate cancer.Is there such a thing as a cancer treatment that isn't worth its cost?Decision Making in a Data-Poor Environment: Management of Brain Metastases From Testicular and Extragonadal Germ Cell Tumors.Social disparities and prostate cancer: mapping the gaps in our knowledge.Management of clinical stage I nonseminomatous germ cell testicular cancer.Controversies in the management of early-stage germ cell tumors.Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.High-priority topics for cancer quality measure development: results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit.Quality of life among testis cancer survivors.Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.Management of poor-prognosis testicular germ cell tumors.Ethical decision-making in critical care in Hong Kong.Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors.The new data on prostate cancer screening: what should we do now?Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration.Health and quality of life among survivors of testis cancer.Testicular cancer survivorship.Impact of race on survival in men with metastatic hormone-refractory prostate cancer.Racial differences in screening for prostate cancer in the elderly.A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance.Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib.Republication of SEMPET trial data?To better manage cancer symptoms.Chemotherapy Is the Preferred Treatment for Seminomas Relapsing After First-line Chemotherapy.Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline.Talking About Death.Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.The ASCO Quality Training Program: designing and implementing a medical specialty society-based quality improvement training program.The REDE Model of Healthcare Communication: Optimizing Relationship as a Therapeutic Agent.Intertubular growth in pure seminomas: associations with poor prognostic parametersCarboplatin for Stage I SeminomaEnd-of-life discussions with patients. Timing and truth-tellingWithdrawing life support: extubation and prolonged terminal weans are inappropriateHow to withdraw mechanical ventilation: more studies are neededRapid withdrawal of support
P50
Q26865075-78A6A130-673C-4DEF-AE24-90689EDEDB9BQ33364671-39CAE5D1-B31C-4724-A3CA-86B41CB99A5BQ34034849-39848A90-DFEB-4AA8-881F-31A6E4A4B1DFQ34856744-DB9656D7-A78B-46DD-801D-B86196E37B8DQ35705230-DC252D11-99B4-4DB2-827C-540B33486B0AQ35868904-5666A1C8-A8EE-4843-B91B-E9EB80DB248EQ36063419-A9EDDEEF-95C2-438E-8CCD-E7E02A2CE2E0Q36813389-CD35EB40-0DAB-4215-8B53-855ECB8468DDQ37428192-53518AD3-E6A2-4DED-BA47-0AB97A48EDB4Q37943995-5623D84C-E1A9-465E-9A9F-A8F279B65317Q38189254-9F4139A9-8AD8-4FFB-B2D8-9DB4C5DAEA97Q38531339-BD6F685F-F3B0-4FE0-97EE-762732963830Q39393942-64F47BEF-F081-4811-BEBE-53FF19BD3271Q39720586-B802D3B0-0854-435C-A961-9560D475F255Q40810851-FD06C9B5-7CEF-4401-AE79-17926AF1FA71Q41721983-EF86F481-DA9A-4A13-8BAB-4FBDC7BFDD67Q42921533-00630E19-BD04-49EA-A329-B3C5AD8F6F1BQ43041924-0C5A8641-AD9E-4C02-9EAE-212E4DBED39AQ43869849-44B73C3C-0983-49CA-9A98-3865549B3E37Q44541698-83494883-3510-4BA3-8B07-734F087A1E32Q44727202-544C7688-6385-46C5-B312-40CFDD8BD676Q44810639-E4EA41AC-771A-4821-8CD5-EEA91F215EF0Q45012353-3897F396-63AF-4C70-B39E-639B9C0CB06CQ46741987-37F66B74-EDCD-4377-8A0E-C71817A65D2AQ46758620-B7A53AFC-98F5-4330-B660-8B4C65D32A9AQ46884239-0F6E833F-B964-4C0D-B50E-1686C94ECE83Q46904472-3BB02FB5-291E-4A0A-AE4A-CBB23AE48DAAQ48715349-0A877521-1F0F-44D1-A513-5B2CD78B8CCDQ49562328-884BA48A-2613-4867-83D6-619A413BB32EQ50156148-5FC1B78C-85B2-4DA1-A2F2-0F86FE112F77Q50207051-B547469B-6FDD-4ACE-A641-478F1CA82AD3Q50526344-E5976909-D5CD-4EA8-B492-A5AC04138A3AQ53548716-AFC2C35C-BB0E-4AAD-8625-E9FD0997231EQ54940394-85933B1A-0EAC-4A5F-993F-1D0C93408C17Q57693554-75C1047A-2F17-4A6C-8D8C-5C27B7BFB8B5Q60156295-E2282A85-BCCC-4E41-AEFB-08C92352722AQ70867362-C207EDA9-7659-4B87-8DCD-7420A0918A00Q71011698-45588D87-5669-4211-B2F4-E9CAFCC552DFQ71685877-A29E895F-FEF5-432F-AE45-B2F021B7C6FCQ71810478-FB4497ED-98DF-4A2F-BEB0-83DE1C562669
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Timothy D Gilligan
@ast
Timothy D Gilligan
@en
Timothy D Gilligan
@es
Timothy D Gilligan
@nl
type
label
Timothy D Gilligan
@ast
Timothy D Gilligan
@en
Timothy D Gilligan
@es
Timothy D Gilligan
@nl
prefLabel
Timothy D Gilligan
@ast
Timothy D Gilligan
@en
Timothy D Gilligan
@es
Timothy D Gilligan
@nl
P106
P1153
7004267087
P31
P496
0000-0003-2308-9303